Levopidon

Levomethadone Hydrochloride, the active ingredient in Levopidon, is an opioid analgesic presented as an oral formulation for oral use. It is employed in the management of opioid dependence and for the relief of chronic pain in adult patients. GNH USA supplies Levopidon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levopidon is an opioid medication used in the treatment of conditions that involve opioid dependence and severe pain. - Opioid dependence: assists with withdrawal management and maintenance therapy. - Chronic pain: provides analgesia for persistent moderate‑to‑severe pain. - Severe pain unresponsive to other opioids: offers an alternative analgesic option when standard opioids are insufficient.

Adverse reactions may occur with Levopidon use.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel movements. - Drowsiness: increased sleepiness or fatigue. - Dry mouth: reduced salivation. - Dizziness: light‑headed sensation. - Sweating: excessive perspiration.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - QT interval prolongation: potential cardiac arrhythmia. - Severe hypotension: marked drop in blood pressure. - Seizures: convulsive episodes. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

Before initiating Levopidon therapy, several safety considerations are recommended. - Assess respiratory function: ensure adequate ventilation before dosing. - Monitor liver function: levomethadone is hepatically metabolised. - Evaluate substance‑use history: identify risk of misuse or diversion. - Avoid concurrent CNS depressants: limit use with benzodiazepines or alcohol. - Use caution in renal impairment: adjust monitoring as needed. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Levopidon can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Other opioids: additive respiratory depression risk. - Central nervous system depressants (e.g., benzodiazepines): heightened sedation. - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): increased levomethadone levels. - CYP3A4 inducers (e.g., rifampin): reduced efficacy. - QT‑prolonging agents (e.g., certain antiarrhythmics): monitor cardiac rhythm. - Alcohol: may enhance sedative effects.